Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ocumension Therapeutics
  6. News
  7. Summary
    1477   KYG674111011

OCUMENSION THERAPEUTICS

(1477)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New Drug OT-202 in China

10/12/2021 | 12:25am EST

Ocumension Therapeutics on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group. The board (the "Board") of directors of the Company announced that OT-202 (tyrosine kinase inhibitor), a class I new drug self-developed by the Company for the treatment of dry eye, was approved by the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration of the People's Republic of China to conduct clinical trial on the treatment of dry eye in China. OT-202 (tyrosine kinase inhibitor) is a class I new drug developed for the treatment of dry eye. The core mechanism of dry eye is mainly due to a variety of factors and diseases caused by the decrease in tear production or high evaporation, which leads to hypertonicity of tears. This hypertonic state activates by a series of inflammations on the ocular surface and releases inflammatory mediators into the tears fluid, and thus the cycle continues. The key treatment for dry eye is to break the vicious circle of inflammation. Spleen tyrosine kinase (Syk) is a cytoplasmic protein kinase, which plays a key role in a variety of biological functions, including classical immunoreceptor such as activating Fc receptors (FcR) and the intracellular signal cascade of B cells receptors (BCRs) that are particularly significant for the initiation of inflammation. Syk inhibitors can be used for the treatment of various allergic diseases, autoimmune diseases and inflammatory diseases. Syk is the target of OT-202, which achieves anti-inflammatory effects by inhibiting the activity of Syk kinase, which has shown significant therapeutic effects and anti-inflammatory effects in the guinea pigs' immune-type dry eye model and the mice's scopolamine dry eye model. The toxicology studies have also shown that it is well-tolerated in the body of animals.


ę S&P Capital IQ 2021
All news about OCUMENSION THERAPEUTICS
01/05Ocumension Therapeutics Enrolls First Patient in Clinical Trial of Dry Eye Treatment in..
MT
01/04Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-..
CI
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
MT
2021OCUMENSION THERAPEUTICS : China Approves Clinical Trial of Ocumension Therapeutics Drug fo..
MT
2021Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New D..
CI
2021Ocumension Therapeutics Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
2021OCUMENSION THERAPEUTICS' : Phase 3 Clinical Trial Application for Eye Inflammation Treatme..
MT
2021Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical ..
CI
2021OCUMENSION THERAPEUTICS : Snaps Up Interests In Two Eye Drugs In China From Novartis
MT
2021OCUMENSION THERAPEUTICS : Acquires all the Equity Interests in Two Ophthalmic Products Mai..
PR
More news
Financials
Sales 2021 72,9 M 11,5 M 11,5 M
Net income 2021 -438 M -68,8 M -68,8 M
Net cash 2021 1 711 M 269 M 269 M
P/E ratio 2021 -18,5x
Yield 2021 -
Capitalization 8 001 M 1 027 M 1 257 M
EV / Sales 2021 86,2x
EV / Sales 2022 25,1x
Nbr of Employees 187
Free-Float -
Chart OCUMENSION THERAPEUTICS
Duration : Period :
Ocumension Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUMENSION THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 12,00 CNY
Average target price 23,86 CNY
Spread / Average Target 98,9%
EPS Revisions
Managers and Directors
Ye Liu Chief Executive Officer & Executive Director
Jian Ping Yang Finance Director
Lian Yong Chen Executive Chairman
Chang Dong Liu Chief Scientific Officer
Dong Hong Chen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OCUMENSION THERAPEUTICS-31.43%1 084
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642